34.75
前日終値:
$34.58
開ける:
$34.61
24時間の取引高:
3.34M
Relative Volume:
1.50
時価総額:
$4.34B
収益:
$1.12B
当期純損益:
$5.00M
株価収益率:
3,475.00
EPS:
0.01
ネットキャッシュフロー:
$-383.00M
1週間 パフォーマンス:
+3.86%
1か月 パフォーマンス:
+6.79%
6か月 パフォーマンス:
+48.12%
1年 パフォーマンス:
+253.51%
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
名前
Indivior Pharmaceuticals Inc
セクター
電話
804-379-1090
住所
234 BATH ROAD, SLOUGH, BERKSHIRE
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
INDV
Indivior Pharmaceuticals Inc
|
34.75 | 4.32B | 1.12B | 5.00M | -383.00M | 0.01 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.26 | 58.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.56 | 53.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.23 | 49.87B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.41 | 39.57B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
482.42 | 20.39B | 3.13B | 1.27B | 1.12B | 26.39 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-22 | 再開されました | Jefferies | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
すべてを表示
Indivior Pharmaceuticals Inc (INDV) 最新ニュース
Indivior Pharmaceuticals, Inc. (INDV) Investor Outlook: Navigating a 34.59% Potential Upside - DirectorsTalk Interviews
New York State Common Retirement Fund Sells 56,140 Shares of Indivior PLC $INDV - MarketBeat
Indivior Pharmaceuticals (INDV) Stock Analysis: A 30% Upside Opportunity Amidst Promising Drug Innovations - DirectorsTalk Interviews
Jackson Creek Investment Advisors LLC Buys Shares of 60,890 Indivior PLC $INDV - MarketBeat
Federated Hermes Inc. Makes New $8.12 Million Investment in Indivior PLC $INDV - MarketBeat
How Opvee, Indivior’s powerful overdose antidote, went bust - statnews.com
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ - The Manila Times
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on ... - Caledonian Record
Indivior’s Stock Under Pressure: Can the Addiction-Treatment Specialist Regain Investor Trust? - AD HOC NEWS
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum Breakout Setup - Chartmill
Will Indivior’s (INDV) US Headquarters Shift and Larger ESOP Shelf Reshape Its Corporate Narrative? - simplywall.st
Indivior completes redomiciliation from UK to US By Investing.com - Investing.com Nigeria
Aug PreEarnings: Is Indivior PLC vulnerable to short sellersQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Indivior announces completion of redomiciliation to U.S. - TipRanks
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq - GuruFocus
Indivior Completes U.S. Domestication and Governance Realignment - TipRanks
Indivior Announces Completion of Redomiciliation to the United States - The Manila Times
Indivior completes redomiciliation from UK to US - Investing.com
Indivior Signs Note Purchase Agreement Amendment With Piper Sandler Finance - TradingView
Indivior PLC: Can a Focused Addiction-Treatment Portfolio Power the Next Wave of Growth? - AD HOC NEWS
Is Indivior PLC forming higher highs and higher lowsJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - mfd.ru
(INDV) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
VELA Investment Management LLC Raises Stock Position in Indivior PLC $INDV - MarketBeat
Indivior’s 2026 Revenue Guidance Tightens Expectations Might Change The Case For Investing In Indivior (INDV) - Yahoo Finance
Q1 Earnings Forecast for Indivior Issued By Northland Capmk - MarketBeat
Indivior PLC (INDV) Investor Outlook: A 35.66% Potential Upside With Strong Buy Ratings - DirectorsTalk Interviews
Aug Selloffs: Can Indivior PLC stock outperform in a bear marketJuly 2025 Technicals & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Indivior PLC: Can a Focused Addiction-Treatment Specialist Win the Next Decade of Mental Health Phar - AD HOC NEWS
Grail and Indivior PLC come out on top in healthcare quant picks ahead of Q4 earnings - MSN
Ritholtz Wealth Management Buys Shares of 92,845 Indivior PLC $INDV - MarketBeat
Market Wrap: Will WNEB outperform small cap indexes2025 Sector Review & Trade Opportunity Analysis - baoquankhu1.vn
Short Interest in Indivior PLC (NASDAQ:INDV) Rises By 57.5% - MarketBeat
Indivior (NASDAQ:INDV) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
Indivior PLC: How a Specialist Addiction Franchise Is Quietly Rebuilding a Global Pharma Contender - AD HOC NEWS
Indivior (INDV) Price Target Increased by 13.21% to 43.71 - Nasdaq
Q1 Earnings Forecast for Indivior Issued By HC Wainwright - MarketBeat
Portfolio Update: Is now the right time to enter Indivior PLCJuly 2025 Chart Watch & Accurate Entry/Exit Alerts - baoquankhu1.vn
Indivior PLC (INDV) Stock Analysis: Exploring a 24% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Aug Setups: Does Indivior PLC stock trade at a discount to peersMarket Activity Summary & Safe Capital Growth Tips - Bộ Nội Vụ
Risks Report: Will Indivior PLC stock remain a Wall Street favorite2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
HC Wainwright Estimates Indivior's Q2 Earnings (NASDAQ:INDV) - MarketBeat
51,426 Shares in Indivior PLC $INDV Purchased by KLP Kapitalforvaltning AS - MarketBeat
Volume Recap: Is Indivior PLC forming higher highs and higher lows2025 Market Sentiment & Verified Entry Point Signals - baoquankhu1.vn
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus - Yahoo Finance
Indivior stock price target raised to $48 from $35 at H.C. Wainwright - Investing.com Nigeria
INDV: Analyst Raises Price Target to $48.00, Maintains Buy Ratin - GuruFocus
Naloxone Market Is Going to Boom |EMERGENT, Indivior PLC, Akorn, Inc - openPR.com
Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance - Finviz
Indivior (NasdaqGS:INDV) Valuation Check After Strong Long Term Returns And Recent Price Consolidation - Yahoo Finance
Indivior Pharmaceuticals Inc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):